From the Early Days in Oncology to Now

Video

In this interview Dr. Armitage discusses his early career and what led him to specialize in the treatment of lymphoma, and shares his thoughts on the future of cancer treatment.

At the ASCO 2014 Annual Meeting, James O. Armitage, MD, professor in the department of internal medicine at the University of Nebraska Medical Center and editor in chief of ONCOLOGY, received the Special Recognition Award to celebrate his accomplishments in the fields of oncology and hematology. In this interview, Dr. Armitage discusses his early career and what led him to specialize in the treatment of lymphoma, and shares his thoughts on the biggest present-day issues in oncology and the future of cancer treatment.

Recent Videos
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Related Content